Education research activities

■ Journal

1.		Monolayer Cultrure of Human Adult Pancreas. 1982/09
2.		Presence of a limited number of essential nucleotides in the promoter region of mouse ribosomal RNA gene. 1985/05
3.		Variation among mouse ribosomal RNA genes within and between chromosomes. 1987/11
4.		Molecular genetic mapping of mouse obese (ob) gene by backcross system of mus musculus. Keystone Symposia on molecular and cellular biology. 1989/01
5.		Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. 1990/04
6.		Factors controlling trypsin-activated peptide kinase in healthy and diabetic men. 1991/09
7.		Hemimethylation and Hypersensitivity Are Early Events in Transscriptional Reactivation of Human Inactive X-Linked Genes in a Hamster X Human Somatic cell Hybrid. 1992/09
8.		Retinoid inhibition on insulin-stimulated Kemptide kinase in cell differentiation. 1994/09
9.		Preferential transmission of maternal allele with DQA1^0301-DQB1^0302 haplotype to affected offspring in families with type 1 diabetes. 1999/04
10.		Differentiation-Induced Insulin Secretion from Norendocrine Cells with Engineered Human Proinsulin cDNA. 1999/11
11.		PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients 2002/01
12.		Differential effect of PPARgamma2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans 2002/08
13.		Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. 2002/09
14.		Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2.Piccolo complex in cAMP-dependent exocytosis 2002/12
15.		Obesity and type 2 diabetes in Japanese patients． 2003/01
16.		Gene and cell-based therapy for diabetes mellitus: endocrine gene therapeutics 2003/06
17.		Design and basic characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mild elevated cholesterol levels. 2004/06
18.		Enhanced Insulin Secretion from Engineered 3T3-L1 preadipocytes by Induction of cellular differentiation. 2005/01
19.		The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions: additional analysis from the Japan Diabetes Complications Study. 2006/01
20.		Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 2006/09
21.		A Case of Prolactin Deficiency with Familial Puerperal Alactogenesis Accompanying Impaired ACTH Secretion. 2007/02
22.		In vitro and Pathological Investigations of MODY5 with the R276X-HNF1β(TCF2) Mutation. 2007/05
23.		Cross-sectional association between BMI, glycemic control and energy intake in Japanese patients with type 2 diabetes. Analysis from the Japan Diabetes Complications Study. 2007/09
24.		Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. 2007/09
25.		Epistatic Interaction of LPL and PPARγ Genes in Adipocytes by Exposure to Dioxin. 2008/06
26.		Persistent Pituitary Hyperplasia In Primary Hypothyroidism Despite Levothyroxine Therapy. 2009/06
27.		Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. 2010/04
28.		Novel Hormonal Delivery Method Using the Ink-Jet Technology: Application to Pulmonary Insulin Therapies. 2011/05
29.		Temporal and Spatial Cellular Distribution of Neural Crest Derivatives and Alpha Cells during Islet Development. 2012/02
30.		Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. 2014/03
31.		Epigenetics: Reprogrammable interface of the genome and environments. 2014/03/23
32.		Inhibitory effect of p53 on mitochondrial content and function during adipogenesis. 2014/03/28
33.		Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. 2014/07
34.		Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. 2014/07
35.		Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. 2014/07
36.		Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial. 2015/04
37.		Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males. 2015/05
38.		Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. 2015/05
39.		Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. 2015/07
40.		High-throughput screening of small interfering ribonucleic acid identifies important modulators in islet dysfunction and apoptosis. (Commentary) 2015/07
41.		Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. 2016/01/01
42.		Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials. 2016/04
Display 5 items
Display all(42)

■ BooK

1.

糖尿病・肥満．、, イラストによる外来患者の指導；インフォームドコンセントをめざして． 1995/06

■ Academic background

1.	1974/04～1980/03	Faculty of Medicine, The Jikei University School of Medicine, Graduated,
2.	1983/07～1986/04	Faculty of Medicine, The University of Tokyo,

■ Presentation

1.	Molecular Genetic mapping of mouse obese (ob) gene by backcross system of MUS MUSCULUS. （Poster notice） 1989/04/01
2.	Demethylation-induced reactivation of X-linked genes on the inactive human X chromosome. 1991/10
3.	Possible role of genomic imprinting at HLA-DQ/DR region in the pathogenesis of insulin-dependent diabetes mellitus. （Speech，General） 1994/10
4.	Down regulation of mRNA level for X-linked genes and haploinsufficiency associated with male sex chromosome aneuploidy. （Speech，General） 1997/10/15
5.	Ex vivo and in vivo characterization of a novel genetically-engineered insulin-secreting cell line. （Speech，General） 2001/06/10
6.	“Surrogate cell therapy” for diabetes and “regeneration” of pancreas. （Speech，Special/Invited Lecture） 2004/05/05
7.	Induction of furin during cellular differentiation　is associated with enhanced secretion of insulin from genetically engineered progenitor cells. （Poster notice） 2005/06
8.	Future prospects of DPP-IV inhibitor. Symposium: Incretin, from pathology to therapeutic implication. （Speech，Panelist at Symposium/Workshop (Appointed)） 2006/05/26
9.	In Vivo Gene Delivery by Pancreatic Direct Injection of rAAV8 Vector Is Efficient Exclusively to the Injured Islets. （Poster notice，General） 2007/06/10
10.	Recent Advance In Molecular And Cellular Therapy. 2008/04
11.	Reversal in beta cell mass and glucose tolerance of diabetic mice by reactivation of Cyclin-dependent kinases with in vivo gene transfer. （Poster notice，General） 2008/09
12.	PKCdelta Induces Pancreatic beta Cell Death in a Nix-Dependent Manner. （Speech，General） 2011/06
13.	TS-071, a Novel and Selective SGLT2 Inhibitor, Improved Glycemic Control and Decreased Body Weight in 12-Week Study of Japanese Patients with Type 2 Diabetes Mellitus. （Poster notice） 2011/06
14.	TS-071, a Novel, Potent and Selective SGLT2 Inhibitor, Induced Dose-Related Increase of Urinary Glucose Excretion and Showed Good Tolerability in Japanese Healthy Male Subjects. （Poster notice） 2011/06
15.	A novel potent and highly selective renal sodium-glucose co-transporter 2(SGLT2) inhibitor, TS-071, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. （Speech） 2011/09
16.	TS-071, a novel potent and highly selective renal sodium-glucose co-transporter 2(SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. （Poster notice，General） 2011/09
17.	The effect of Luceogliflozin (TS-071), a selective SGLT2 inhibitor, on pharmacodynamics and pharmacokinetics in Japanese type 2 diabetic subjects with renal impairment. （Poster notice，Special/Invited Lecture） 2012/06/08
18.	Effects of gender and age on the pharmacokinetics and pharmacodynamics of Luceogliflozin (TS-071), a selective SGLT2 inhibitor. （Poster notice，General） 2012/06/09
19.	Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. （Poster notice，General） 2012/06/09
20.	Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycaemic control and lowers body weight in a 12-week study in Japanese patients with type 2 diabetes mellitus. （Poster notice，General） 2012/09
21.	Dru-drug interactions of Luseoglifozin (TS-071) with other oral hypoglycemic agents in healthy Japanese subjects. （Poster notice，General） 2012/11/27
22.	Luseogliflozin, a SGLT2 inhibitor, as add-on therapy to 5 types of oral antidiabetic drugs improves glycemic control and reduces body weight in Japanese patients with type 2 diabetes mellitus. （Poster notice） 2013/09
23.	Luseogliflozin, a SGLT2 inhibitor, improves glycaemic control and reduces body weight as monotherapy up to 52 weeks in Japanese patients with type 2 diabetes mellitus. （Poster notice） 2013/09
24.	Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients. （Speech，General） 2013/09/26
25.	Consistent efficacy of add-on combination of luceogliflozin with conventional oral antidiabetic drugs in Japanese patients with T2DM. （Poster notice） 2013/12
26.	Luseogliflozin, a selective SGLT2 inhibitor, improves glycemic control as monotherapy in Japanese patients with T2DM. （Poster notice） 2013/12
27.	Efficacy and Safety of Luseogliflozin in Various Levels of Renal Function in　Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Pooled Data From Long-term Phase 3 Trials. 2014/06/15
28.	Long-term Efficacy and Safety of Luseogliflozin,an SGLT2 Inhibitor,in Elderly Patients with Type 2 Diabetes 74th Scientific Sessions, The American Diabetes Association. （Poster notice，General） 2014/06/15
29.	PKCdelta is a key regulator of palmitate-induced beta cell death. （Poster notice） 2015/09
Display 5 items
Display all(29)

■ Business career

1.	1990/04～1992/03	University of Washington Division of Medical Genetics, Department of Genetics Senior Fellow
2.	1980/05～1982/04	The Jikei university School of Medicine

■ Home Page

http://www.jikei.ac.jp/academic/course/22_rinsho.html

http://www.jikei.ac.jp/hospital/kashiwa/sinryo/07_b.html

■ E-Mail Address

■ Present specialized field

Metabolism and endocrinology, Metabolism and endocrinology, Medical biochemistry